Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG (MOLN) is a clinical-stage biotech company whose news flow is closely tied to the progress of its DARPin-based oncology pipeline. The company regularly issues updates on its clinical trials, preclinical data presentations and strategic collaborations, giving investors and observers insight into how its programs are advancing through development.
News about Molecular Partners often highlights milestones for its Radio-DARPin platform, including MP0712, a 212Pb-based candidate targeting DLL3 in small cell lung cancer and other neuroendocrine cancers, and MP0726, which targets mesothelin in cancers with high unmet need. Press releases describe regulatory steps such as Investigational New Drug applications, initiation of Phase 1/2a studies, and early human imaging data from compassionate care programs, as well as the role of its collaboration with Orano Med in radiotherapeutics.
Another major source of updates is the companys multispecific T cell engager MP0533, in Phase 1/2a for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome/AML. Molecular Partners reports interim clinical data, dosing refinements and response patterns, particularly in patients with lower disease burden, through conference presentations and ad hoc announcements. News items also cover MP0317, a tumor-localized CD40 agonist in an investigator-initiated Phase 2 trial in cholangiocarcinoma, and preclinical Switch-DARPin programs that use logic-gated immune activation.
Corporate communications further include quarterly and half-year financial results, cash runway commentary, and management changes such as the appointment of a Chief Scientific Officer. For readers following MOLN stock, this news page provides a centralized view of regulatory disclosures, scientific conference presentations and pipeline progress updates related to Molecular Partners DARPin therapeutics.
Molecular Partners (NASDAQ: MOLN) will present updated Phase 1/2a data for MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), at the ASH Annual Meeting on December 7, 2025.
The poster summarizes first-in-human, multicenter, open-label results in relapsed/refractory AML and MDS/AML (ClinicalTrials.gov: NCT05673057). MP0533 showed an acceptable safety profile across dose ranges 1–9; densified dosing used in DR 8–9 appears tolerable and preliminary antitumor activity is described. The study is dosing in DR 10. Abstracts posted on the ASH website from 9:00 AM ET on November 3, 2025.
Molecular Partners (NASDAQ:MOLN / SIX:MOLN) filed an IND for MP0712 (212Pb DLL3 Radio-DARPin) with a Phase 1 start expected before year-end 2025 and first compassionate-care 203Pb images to be shown at the TRP Summit in November. Updated MP0533 Phase 1/2a data (AML) will be presented at ASH in December, with cohort 8 showing 3 of 8 evaluable responders and one patient >12 months on treatment.
Protocol approved for a Phase 2 investigator-initiated trial of MP0317 (FAP x CD40). Cash, equivalents and short-term deposits were CHF 105 million as of Sept 30, 2025, and the company expects runway until 2028. Full‑year 2025 operating expense guidance: CHF 55–60 million.
Molecular Partners (NASDAQ:MOLN) reported H1 2025 financial results and pipeline updates, highlighting progress in its clinical programs. The company's lead candidate MP0533 for AML/MDS showed promising results with >30% response rate in cohort 8, including durable responses. Their radio-DARPin program MP0712 is advancing toward Phase 1 trials, with IND filing expected by end of 2025.
The company appointed Martin Steegmaier, Ph.D. as CSO and announced a workforce reduction of up to 24%. With CHF 114 million in cash and deposits as of June 30, 2025, Molecular Partners has extended its runway into 2028. Expected operating expenses for 2025 are CHF 55-65 million.
Molecular Partners (NASDAQ:MOLN) has appointed Martin Steegmaier, Ph.D. as Chief Scientific Officer (CSO) and member of the Executive Committee, effective October 1, 2025. Dr. Steegmaier brings extensive oncology drug development experience from his previous roles at SOTIO Biotech, MorphoSys, Roche, and Boehringer Ingelheim.
As CSO, Steegmaier will lead the research organization and advance the company's pipeline of targeted DARPin therapeutics for cancer patients, including Radio-DARPins and Switch-DARPins for logic-gated immune cell activation. His background includes significant experience in developing antibody-based therapeutics in immuno-oncology and hematology-oncology.
Molecular Partners (NASDAQ: MOLN) reported Q1 2025 financial results and key milestones. The company maintains a strong cash position of CHF 131 million as of March 31, 2025, providing funding into 2027. Two significant developments include:
1. The expansion of their partnership with Orano Med from 4 to 10 programs for Radio-DARPin therapies, with MP0712 progressing toward IND filing and initial clinical data expected in 2025.
2. Positive progress in the MP0533 Phase 1/2a trial, with cohort 8 showing increased response rates and depth in AML treatment. The study protocol has been amended and cohort 9 enrollment has begun.
The company expects total operating expenses of CHF 55-65 million for 2025, with approximately CHF 7 million in non-cash costs.
Molecular Partners (NASDAQ: MOLN) presented three significant developments at AACR 2025:
- Positive IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 for small cell lung cancer, with clinical development starting in 2025
- Initial preclinical data on a new mesothelin-targeting Radio-DARPin for solid tumors
- Preclinical proof-of-concept data for a logic-gated CD3 Switch-DARPin T cell engager
The MP0712 program showed high tumor uptake and favorable safety profiles in mouse models. The mesothelin-targeting Radio-DARPin demonstrated strong tumor accumulation while avoiding interference from shed mesothelin. The Switch-DARPin technology showed specific T cell activation in the presence of target cells and achieved tumor regression in mice without peripheral T cell activation.